Inspire Medical Systems, Inc.
$1.60B- Market cap
- $1.79B
- Debt
- +$112.36M
- Cash
- −$308.27M
Capital structure 94% equity / 6% debt · EV / Revenue 1.75x · EV / EBITDA 24.29x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: INSP stock price at premium vs IART $62.08 current versus $24.26 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at IART's multiple
Implied fair value · at INSP's multiple
Snapshot Sep 8, 10:48 AM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: INSP FY 2025 (ended Dec 31, 2025) · IART FY 2025 (ended Dec 31, 2025).
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 1.75x · EV / EBITDA 24.29x
Capital structure 63% equity / 37% debt · EV / Revenue 1.05x
IART carries the larger enterprise value at $1.72B against $1.60B; IART trades on the lower EV / Revenue multiple (1.05x vs 1.75x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Inspire Medical Systems, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
INTEGRA LIFESCIENCES HOLDINGS CORP · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.14x
0.70x
Net debt / EBITDA
Leverage against operating earnings
-2.98x
-0.92x
Cash and equivalents
Liquid reserves on the balance sheet
$308.27M
$263.74M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BOSTON SCIENTIFIC CORP
INSP vs BSX
Medtronic plc
INSP vs MDT
ABBOTT LABORATORIES
INSP vs ABT
JOHNSON & JOHNSON
INSP vs JNJ
LivaNova PLC
INSP vs LIVN
ZIMMER BIOMET HOLDINGS, INC.
INSP vs ZBH
STRYKER CORP
INSP vs SYK
BECTON DICKINSON & CO
INSP vs BDX
Edwards Lifesciences Corp
INSP vs EW
BAXTER INTERNATIONAL INC
INSP vs BAX
TELEFLEX INC
INSP vs TFX
$112.36M
$726.56M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.